Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.6400 (0.24%) ($12.5600 - $12.6400) on Thu. Feb. 9, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.54% (three month average) | RSI | 45 | Latest Price | $12.6400(0.24%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.3% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(54%) IWO(45%) IWM(44%) IWC(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.27% in a week (0% probabilities). TBT(-18%) UUP(-11%) VIXM(-10%) VCSH(-6%) EDOC(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.27% (StdDev 2.54%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12.98 | 5 Day Moving Average | $12.85(-1.63%) | 10 Day Moving Average | $12.95(-2.39%) | 20 Day Moving Average | $12.98(-2.62%) | To recent high | -6.3% | To recent low | 18.3% | Market Cap | $3.264b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |